Tanja Dowe
Chief Executive Officer @ Debiopharm Innovation Fund
Lausanne, Switzerland
Tanja Dowe is a Series A investor at Debiopharm Innovation Fund in Lausanne focused on Health Care and Artificial Intelligence. Tanja Dowe is based out of Lausanne, Vaud, and is the Board Director of Hypervision Surgical. Tanja previously worked at Reaktor as a Board Member. Tanja Dowe attended Teknillinen korkeakoulu-Tekniska högskolan.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Tanja Dowe invests in
Stages Tanja Dowe invests in
Countries Tanja Dowe invests in
Investment Focus
Industry
- Health Care 7 (78%)
- Artificial Intelligence 5 (56%)
- Machine Learning 3 (33%)
- Biotechnology 2 (22%)
- Medical Device 2 (22%)
Stage
- Series A 7 (78%)
- Series B 2 (22%)
Country
- Belgium 2 (22%)
- United States 2 (22%)
- France 1 (11%)
- Israel 1 (11%)
- Germany 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hypervision Surgical
|
Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging. | $23M / Series A / Apr 29, 2026 | |
Nobi
|
Nobi is a smart lamp that ensures help can be provided in a flash in the event of a fall. It recognizes a fall, and it will notify a family member, contacts, or a specialized emergency call center. The lamp will then connect to that person to reassure them that help is on the way. If necessary, it can even unlock the smart lock on the front door. | $36.5M / Series B / Jan 28, 2025 | |
Iktos
|
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. | $16.4M / Series A / Mar 09, 2023 | |
Mika
|
Mika is a digital platform that empowers cancer patients. It aims to help improve cancer patients' mental health and well-being. Mika was created in collaboration with leading research institutions. The company was established in 2017 and is headquartered in Berlin, Germany. | $10.6M / Series A / May 09, 2022 | |
VivoSense
|
VivoSense, also known as Vivonoetics are a data analysis and software company specializing in wearable sensor physiological monitoring solutions for research and clinical trials. | $25M / Series A / Mar 30, 2022 | |
Nucleai
|
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $33M / Series B / Mar 22, 2022 | |
VeriSIM Life
|
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, largemolecules, and viruses. | $15M / Series A / Jan 13, 2022 | |
Oncomfort
|
Oncomfort’s solution for digital sedation is a completely new method for relieving patients’ pain and anxiety before, during and after medical procedures. This revolutionising digital therapy combines clinical hypnotherapy and integrative therapeutic techniques through Virtual Reality. | $11.8M / Series A / Sep 09, 2020 | |
|
Nucleai
|
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $8.5M / Series A / Jul 07, 2020 |
Co-Investors
About Debiopharm Innovation Fund
Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflowsolutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.
Debiopharm Innovation Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cedric Odje
Senior Investment Associate
|
|||
|
Nicole Wilson
Senior Administrative Assistant
|
|||
|
Tanja Dowe
Chief Executive Officer
|
|||
Thomas Gibbs
Director
|
|||
Vincent Lepreux
Investment Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Tanja Dowe invest in?
Tanja Dowe invests primarily in Health Care, Artificial Intelligence and Machine Learning startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Tanja Dowe last invest?
The most recent investment recorded for Tanja Dowe closed in Apr 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
